BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73. [PMID: 19755966 DOI: 10.1038/ajg.2009.508] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102:1-7. [PMID: 29075827 DOI: 10.1007/s00253-017-8535-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 13.4] [Reference Citation Analysis]
2 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Bricker-Ford R. Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. J Pharm Pract 2021;:8971900211033143. [PMID: 34269127 DOI: 10.1177/08971900211033143] [Reference Citation Analysis]
4 Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380-1384. [PMID: 25229983 DOI: 10.1097/meg.0000000000000197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
5 Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
7 Tang X, Shen Y, Hu R, Yang T, Benghezal M, Li H, Tang H. Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori. Helicobacter 2020;25:e12703. [PMID: 32453910 DOI: 10.1111/hel.12703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Sereni G, Azzolini F, Camellini L, Formisano D, Decembrino F, Iori V, Tioli C, Cavina M, Di Mario F, Bedogni G, Sassatelli R. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. World J Gastroenterol 2012; 18(33): 4542-4548 [PMID: 22969227 DOI: 10.3748/wjg.v18.i33.4542] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
9 Mugengana AK, Vita NA, Brown Gandt A, Moran K, Agyapong G, Sharma LK, Griffith EC, Liu J, Yang L, Gavrish E, Hevener KE, LaFleur MD, Lee RE. The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infect Dis 2021;7:1044-58. [PMID: 33471519 DOI: 10.1021/acsinfecdis.0c00300] [Reference Citation Analysis]
10 Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am 2016;100:827-50. [PMID: 27235617 DOI: 10.1016/j.mcna.2016.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
11 Veliev AM, Maev IV, Andreev DN, Dicheva DT, Zaborovskii AV, Lobanova EG, Bektemirova LG. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease]. Ter Arkh 2019;91:28-33. [PMID: 32598751 DOI: 10.26442/00403660.2019.08.000382] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sauberan JB, Bradley JS. Antimicrobial Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1499-1531.e3. [DOI: 10.1016/b978-0-323-40181-4.00292-9] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. World J Gastroenterol 2014; 20(18): 5302-5307 [PMID: 24833860 DOI: 10.3748/wjg.v20.i18.5302] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 González-Huezo MS, Rojas-Sánchez A, Rosales-Solís AA, Miranda-Cordero RM, Hinojosa-Ruiz A, Mejía-García E, Cruz-González EG. [Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym]. Rev Gastroenterol Mex. 2012;77:114-118. [PMID: 22921101 DOI: 10.1016/j.rgmx.2012.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 311] [Article Influence: 60.3] [Reference Citation Analysis]
16 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
17 Hsu P, Tsay F, Kao JY, Peng N, Tsai K, Tsai T, Kuo C, Kao S, Wang H, Chen Y, Shie C, Wu D; Taiwan Acid‐related Disease & Microbiota (TARD‐M) Consortium. Equivalent efficacies of reverse hybrid and concomitant therapies in first‐line treatment of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2020;35:1731-7. [DOI: 10.1111/jgh.15034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Ermis F, Tasci ES. Current Helicobacter pylori treatment in 2014. World J Methodol 2015; 5(2): 101-107 [PMID: 26140276 DOI: 10.5662/wjm.v5.i2.101] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
19 Bruce MG, Bruden DL, Morris JM, Reasonover AL, Sacco F, Hurlburt D, Hennessy TW, Gove J, Parkinson A, Sahagun G, Davis P, Klejka J, McMahon BJ. Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska. Epidemiol Infect 2015;143:1236-46. [PMID: 25068917 DOI: 10.1017/S0950268814001770] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
20 Wee EW. Evidence-based approach to dyspepsia: from Helicobacter pylori to functional disease. Postgrad Med 2013;125:169-80. [PMID: 23933904 DOI: 10.3810/pgm.2013.07.2688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kadayifci A, Uygun A, Kilciler G, Kantarcioglu M, Kara M, Ozcan A, Emer O. Low efficacy of clarithromycin including sequential regimens for Helicobacter pylori infection. Helicobacter. 2012;17:121-126. [PMID: 22404442 DOI: 10.1111/j.1523-5378.2011.00924.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
22 Xia W. Competition for Iron Between Host and Pathogen: A Structural Case Study on Helicobacter pylori. In: Nordenfelt P, Collin M, editors. Bacterial Pathogenesis. New York: Springer; 2017. pp. 65-75. [DOI: 10.1007/978-1-4939-6673-8_5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 161] [Cited by in F6Publishing: 156] [Article Influence: 17.9] [Reference Citation Analysis]
24 Chang SS, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther 2015; 6(4): 127-136 [PMID: 26558147 DOI: 10.4292/wjgpt.v6.i4.127] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Cárdenas PA, Garcés D, Prado-Vivar B, Flores N, Fornasini M, Cohen H, Salvador I, Cargua O, Baldeón ME. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis 2020;39:1365-72. [PMID: 32125555 DOI: 10.1007/s10096-020-03854-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
26 Abdelfattah T, Shahab O, Shah TU. Gastric intestinal metaplasia: when to treat? How to treat? Curr Opin Gastroenterol 2021;37:602-8. [PMID: 34432654 DOI: 10.1097/MOG.0000000000000784] [Reference Citation Analysis]
27 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
28 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
30 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pyloriWorld J Gastroenterol 2014; 20(27): 8947-8956 [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis. 2011;32:787-795. [PMID: 21436188 DOI: 10.1093/carcin/bgr054] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
32 Sayer JR, Walldén K, Koss H, Allan H, Daviter T, Gane PJ, Waksman G, Tabor AB. Design, synthesis, and evaluation of peptide-imidazo[1,2-a]pyrazine bioconjugates as potential bivalent inhibitors of the VirB11 ATPase HP0525. J Pept Sci 2021;:e3353. [PMID: 34142414 DOI: 10.1002/psc.3353] [Reference Citation Analysis]
33 Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
34 Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00194. [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27:933-947. [PMID: 24182612 DOI: 10.1016/j.bpg.2013.09.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
36 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
37 Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Sociedad Española de Medicina de Familia y Comunitaria. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Gastroenterol Hepatol 2012;35:725.e1-38. [PMID: 23186826 DOI: 10.1016/j.gastrohep.2012.05.002] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Liu KSH, Hung IFN, Seto WKW, Tong T, Hsu ASJ, Lam FYF, But DYK, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5. [DOI: 10.1136/gutjnl-2013-306120] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
40 Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, Wang HM, Lai KH, Cheng JS, Chen A. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore). 2015;94:e2104. [PMID: 26632893 DOI: 10.1097/md.0000000000002104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
41 Smith SM, Haider RB, O'Connor H, McNamara D, O'Morain C. Practical treatment of Helicobacter pylori: a balanced view in changing times. Eur J Gastroenterol Hepatol. 2014;26:819-825. [PMID: 24892516 DOI: 10.1097/meg.0000000000000130] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
42 Garcia-Mazcorro JF, Suchodolski JS, Jones KR, Clark-Price SC, Dowd SE, Minamoto Y, Markel M, Steiner JM, Dossin O. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol. 2012;80:624-636. [PMID: 22324305 DOI: 10.1111/j.1574-6941.2012.01331.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
43 Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16(31): 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
44 Lin T, Wu D, Tsay F, Tsai K, Tsai T, Peng N, Kao S, Chen W, Chen Y, Hsu P. Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection. Journal of the Chinese Medical Association 2020;83:233-7. [DOI: 10.1097/jcma.0000000000000256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
46 Suerbaum S, Coombs N, Patel L, Pscheniza D, Rox K, Falk C, Gruber AD, Kershaw O, Chhatwal P, Brönstrup M, Bilitewski U, Josenhans C. Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model. mBio 2022;:e0375521. [PMID: 35227071 DOI: 10.1128/mbio.03755-21] [Reference Citation Analysis]
47 Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
48 Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015;42:922-933. [PMID: 26238858 DOI: 10.1111/apt.13346] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
49 Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16(34): 4357-4362 [PMID: 20818821 DOI: 10.3748/wjg.v16.i34.4357] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
50 Basyigit S, Kefeli A, Sapmaz F, Yeniova AO, Asilturk Z, Hokkaomeroglu M, Uzman M, Nazligul Y. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. Bosn J Basic Med Sci 2015;15:50-4. [PMID: 26614852 DOI: 10.17305/bjbms.2015.573] [Reference Citation Analysis]
51 Fakheri H, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: A review. World J Gastroenterol 2014; 20(30): 10355-10367 [PMID: 25132752 DOI: 10.3748/wjg.v20.i30.10355] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
52 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
53 Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, Bielsa-Fernandez MV, Camargo MC, Esquivel-Ayanegui F, Garza-González E, Hernández-Guerrero AI, Herrera-Goepfert R, Huerta-Iga FM, Leal-Herrera Y, Lopéz-Colombo A, Ortiz-Olvera NX, Riquelme-Pérez A, Sampieri CL, Uscanga-Domínguez LF, Velarde-Ruiz Velasco JA. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex (Engl Ed) 2018;83:325-41. [PMID: 29941237 DOI: 10.1016/j.rgmx.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Lee BH, Kim N. Quadruple or triple therapy to eradicate H pylori. The Lancet 2011;377:877-8. [DOI: 10.1016/s0140-6736(11)60168-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
56 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019;34:666-72. [DOI: 10.1111/jgh.14625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
57 Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116:1220-9. [PMID: 33840725 DOI: 10.14309/ajg.0000000000001246] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Hammad TA, Neyarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: An empirical assessment. Clinical Trials 2013;10:389-97. [DOI: 10.1177/1740774513479467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
59 Choi WJ, Do GW, Lee GH. Changes in the Antibiotic Resistance Rates of Helicobacter pylori Strains Isolated in Tertiary Medical Institutions in Seoul. Korean J Med 2014;86:308. [DOI: 10.3904/kjm.2014.86.3.308] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am. 2011;21:613-635. [PMID: 21944414 DOI: 10.1016/j.giec.2011.07.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
61 Lawal TO, Adeniyi BA, Moody JO, Mahady GB. Combination Studies of Eucalyptus torelliana F. Muell. Leaf Extracts and Clarithromycin on Helicobacter pylori: COMBINATION STUDIES OF EUCALYPTUS TORELLIANA ON HELICOBACTER PYLORI. Phytother Res 2012;26:1393-8. [DOI: 10.1002/ptr.3719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
62 Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med. 2014;29:520-528. [PMID: 24065381 DOI: 10.1007/s11606-013-2630-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
63 Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34:604-617. [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 10.5] [Reference Citation Analysis]
64 Puig I, Baylina M, Sánchez-delgado J, López-gongora S, Suarez D, García-iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016;71:2740-53. [DOI: 10.1093/jac/dkw220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
65 Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355-2365. [PMID: 27769562 DOI: 10.1016/s0140-6736(16)31409-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
66 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
67 Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore) 2016;95:e2698. [PMID: 26986096 DOI: 10.1097/MD.0000000000002698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
68 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
69 Huang C, Lai W, Sun M, Lin C, Chen B, Lin H, Chang C, Yang C, Huang K, Yen H. Prescription patterns of traditional Chinese medicine for peptic ulcer disease in Taiwan: A nationwide population-based study. Journal of Ethnopharmacology 2015;176:311-20. [DOI: 10.1016/j.jep.2015.11.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
70 Kobayashi J, Kawakubo M, Fujii C, Arisaka N, Miyashita M, Sato Y, Komura H, Matoba H, Nakayama J. Cholestenone functions as an antibiotic against Helicobacter pylori by inhibiting biosynthesis of the cell wall component CGL. Proc Natl Acad Sci U S A 2021;118:e2016469118. [PMID: 33853940 DOI: 10.1073/pnas.2016469118] [Reference Citation Analysis]
71 Liou JM, Wu MS, Lin JT. Treatment of Helicobacter pylori infection: Where are we now? J Gastroenterol Hepatol. 2016;31:1918-1926. [PMID: 27088632 DOI: 10.1111/jgh.13418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
72 Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One 2018;13:e0189888. [PMID: 29370199 DOI: 10.1371/journal.pone.0189888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
73 Xie Y, Zhang Z, Hong J, Liu W, Lu H, Du Y, Wang W, Xu J, Wang X, Huo L, Zhang G, Lan C, Li X, Li Y, Wang H, Zhang G, Zhu Y, Shu X, Chen Y, Wang J, Lu N; the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018;23:e12496. [DOI: 10.1111/hel.12496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
74 Coelho LG, Maguinilk I, Zaterka S, Parente JM, do Carmo Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol. 2013;50. [PMID: 23748591 DOI: 10.1590/s0004-28032013005000001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
75 Borlace GN, Keep SJ, Prodoehl MJR, Jones HF, Butler RN, Brooks DA. A role for altered phagosome maturation in the long-term persistence of Helicobacter pylori infection. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;303:G169-79. [DOI: 10.1152/ajpgi.00320.2011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
76 Khu JV, Lim LL. Helicobacter pylori Eradication Regimens: Is there a Difference? Journal of Pharmacy Practice and Research 2010;40:194-8. [DOI: 10.1002/j.2055-2335.2010.tb00537.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578-586. [PMID: 23403682 DOI: 10.1001/jama. 2013.311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Najm WI. Peptic ulcer disease. Prim Care. 2011;38:383-394, vii. [PMID: 21872087 DOI: 10.1016/j.pop.2011.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
79 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
80 Yang X, Tan P, Song L, Lu Z. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. American Journal of Therapeutics 2016;23:e1436-41. [DOI: 10.1097/mjt.0000000000000261] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, Chong S, Colletti RB, Casswall T, Elitsur Y. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230-243. [PMID: 21558964 DOI: 10.1097/mpg.0b013e3182227e90] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
82 Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. Expert Rev Gastroenterol Hepatol 2020;14:553-64. [PMID: 32410515 DOI: 10.1080/17474124.2020.1770594] [Reference Citation Analysis]
83 Tirado-Hurtado I, Carlos C, Lancho L, Alfaro A, Ponce R, Schwarz LJ, Torres L, Ayudant M, Pinto JA, Fajardo W. Helicobacter pylori: History and facts in Peru. Crit Rev Oncol Hematol 2019;134:22-30. [PMID: 30771870 DOI: 10.1016/j.critrevonc.2018.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-2636. [PMID: 23167300 DOI: 10.1517/14656566.2012.747510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
85 Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936-5942. [PMID: 25070099 DOI: 10.1128/aac.02922-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
86 Yurenev GL, Partzvania-vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Terapevticheskii arkhiv 2018;90:33-9. [DOI: 10.26442/terarkh201890833-39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Asociación Española de Gastroenterología., Sociedad Española de Medicina de Familia y Comunitaria., Centro Cochrane Iberoamericano. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Aten Primaria 2012;44:727.e1-727.e38. [PMID: 23036729 DOI: 10.1016/j.aprim.2012.05.003] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Sierra F, Forero JD, Rey M. [Ideal treatment for Helicobacter pylori: a systematic review]. Rev Gastroenterol Mex 2014;79:28-49. [PMID: 24365458 DOI: 10.1016/j.rgmx.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
89 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
90 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Seyyedmajidi M, Falaknazi K, Mirsattari D, Zojaji H, Roshani M, Lahmi F, Orimi PG, Hadizadeh M, Zali M. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. Arab J Gastroenterol. 2011;12:150-153. [PMID: 22055594 DOI: 10.1016/j.ajg.2011.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
92 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Gisbert JP. Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol. 2011;8:307-309. [PMID: 21643037 DOI: 10.1038/nrgastro.2011.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
94 Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
95 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
96 Suzuki H, Matsuzaki J, Hibi T. Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication? Expert Rev Clin Pharmacol 2011;4:579-82. [PMID: 22114887 DOI: 10.1586/ecp.11.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
98 Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48:261-264. [PMID: 22147131 DOI: 10.1590/s0004-28032011000400008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
99 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Reference Citation Analysis]
100 Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. [PMID: 21441768 DOI: 10.3810/hp.2011.02.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
101 Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
102 Vakil N, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. J Clin Gastroenterol. 2013;47:383-388. [PMID: 23388847 DOI: 10.1097/mcg.0b013e318277577b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
103 McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, Zakharova NV, Sarsenbaeva AS, Bujanda L, Perez-Aisa Á, Vologzhanina L, Zaytsev O, Ilchishina T, Coba C, Lasala JP, Alekseenko S, Modolell I, Molina-Infante J, Ruiz-Zorrilla Lopez R, Alonso-Galan H, Moreno NF, Hinojosa J, Santaella I, Varela P, Gonzalez-Cordero PL, Barrio J, Dominguez-Jimenez JL, Nuñez O, Alcedo J, Nyssen OP, Caldas M, Donday MG, Shvetz O, Megraud F, O'Morain C, Gisbert JP. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020;18:89-98. [PMID: 30978536 DOI: 10.1016/j.cgh.2019.03.048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
104 Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012;5:103-109. [PMID: 22423259 DOI: 10.1177/1756283x11432492] [Cited by in Crossref: 78] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
105 Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016;40:124-31. [PMID: 26186880 DOI: 10.1016/j.clinre.2015.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
106 Fallone CA, Gisbert JP, Chiba N, Veldhuyzen van Zanten S, Fischbach L, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. Reply. Gastroenterology 2017;152:303-4. [PMID: 27893977 DOI: 10.1053/j.gastro.2016.11.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology 2013;11:507-10. [DOI: 10.1016/j.cgh.2012.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
108 Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013;309:578-86. [PMID: 23403682 DOI: 10.1001/jama.2013.311] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
109 Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
110 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance. World J Gastroenterol 2014; 20(19): 5654-5659 [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
111 Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18:459-467. [PMID: 23714140 DOI: 10.1111/hel.12062] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
112 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34:700-706. [PMID: 30011083 DOI: 10.1111/jgh.14383] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
113 Gavrish E, Shrestha B, Chen C, Lister I, North EJ, Yang L, Lee RE, Han A, Williams B, Charnuska D, Coleman K, Lewis K, LaFleur MD. In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori. Antimicrob Agents Chemother 2014;58:3255-60. [PMID: 24687512 DOI: 10.1128/AAC.02573-13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
114 Malfertheiner P, Bazzoli F, Delchier J, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011;377:905-13. [DOI: 10.1016/s0140-6736(11)60020-2] [Cited by in Crossref: 310] [Cited by in F6Publishing: 117] [Article Influence: 28.2] [Reference Citation Analysis]
115 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
116 Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16:80. [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
117 Owyang SY, Luther J, Owyang CC, Zhang M, Kao JY. Helicobacter pylori DNA’s anti-inflammatory effect on experimental colitis. Gut Microbes. 2012;3:168-171. [PMID: 22356863 DOI: 10.4161/gmic.19181] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
118 Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88. [DOI: 10.1038/nrgastro.2010.210] [Cited by in Crossref: 122] [Cited by in F6Publishing: 129] [Article Influence: 11.1] [Reference Citation Analysis]
119 Hafeez M, Qureshi ZA, Khattak AL, Saeed F, Asghar A, Azam K, Khan MA. Helicobacter Pylori Eradication Therapy: Still a Challenge. Cureus 2021;13:e14872. [PMID: 34113506 DOI: 10.7759/cureus.14872] [Reference Citation Analysis]
120 Buzás GM. Fate of meta-analyses: The case of Helicobacter pyloriWorld J Meta-Anal 2015; 3(1): 20-25 [DOI: 10.13105/wjma.v3.i1.20] [Reference Citation Analysis]
121 Blum FC, Singh J, Merrell DS. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori. J Ethnopharmacol 2019;232:236-43. [PMID: 30578933 DOI: 10.1016/j.jep.2018.12.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
122 Cosme A, Lizasoan J, Montes M, Tamayo E, Alonso H, Mendarte U, Martos M, Fernández-Reyes M, Saraqueta C, Bujanda L. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. Helicobacter 2016;21:29-34. [PMID: 25982426 DOI: 10.1111/hel.12231] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
123 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Reference Citation Analysis]
124 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
125 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 415] [Article Influence: 103.0] [Reference Citation Analysis]
126 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
127 Wu Y, Song Z, Deng G, Jiang K, Wang H, Zhang X, Han H. Gastric Acid Powered Nanomotors Release Antibiotics for In Vivo Treatment of Helicobacter pylori Infection. Small 2021;17:e2006877. [PMID: 33619851 DOI: 10.1002/smll.202006877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
128 Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012;36:222-30. [DOI: 10.1111/j.1365-2036.2012.05165.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
129 Kuo CJ, Chen CW, Le PH, Hsu JT, Lin CY, Cheng HT, Su MY, Lin CJ, Chiu CT. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections. Therap Adv Gastroenterol 2019;12:1756284819870960. [PMID: 31523277 DOI: 10.1177/1756284819870960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]